Vor Biopharma (NASDAQ:VOR) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Vor Biopharma (NASDAQ:VOR) from a sell rating to a hold rating in a report issued on Saturday.

A number of other research analysts have also recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Vor Biopharma in a report on Monday, May 18th. Weiss Ratings upgraded Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a report on Tuesday. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Finally, Wedbush boosted their target price on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vor Biopharma presently has an average rating of “Moderate Buy” and a consensus target price of $43.38.

Vor Biopharma Stock Down 1.1%

NASDAQ:VOR opened at $23.03 on Friday. The firm’s 50 day moving average is $18.55 and its two-hundred day moving average is $16.01. Vor Biopharma has a fifty-two week low of $6.50 and a fifty-two week high of $50.20.

Vor Biopharma (NASDAQ:VOR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). On average, analysts forecast that Vor Biopharma will post -2.7 EPS for the current year.

Hedge Funds Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. RA Capital Management L.P. grew its position in Vor Biopharma by 172.7% in the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after acquiring an additional 3,422,697 shares in the last quarter. Fcpm Iii Services B.V. lifted its position in shares of Vor Biopharma by 852.8% during the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock worth $47,315,000 after purchasing an additional 3,237,714 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new position in shares of Vor Biopharma in the fourth quarter valued at $33,275,000. Paradigm Biocapital Advisors LP purchased a new position in shares of Vor Biopharma in the fourth quarter valued at $22,890,000. Finally, NEXTBio Capital Management LP acquired a new stake in Vor Biopharma during the 4th quarter valued at $13,080,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Key Vor Biopharma News

Here are the key news stories impacting Vor Biopharma this week:

• Positive Sentiment: Wedbush raised its price target to $27. The higher target provides additional support for the stock’s valuation and reflects continued optimism about Vor Biopharma’s long-term prospects. Wedbush Increases Vor Biopharma Price Target to $27.00
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $31 price target. The firm expects continued losses in the near term, including estimated 2027 EPS of negative $3.65, but projects a return to profitability by 2029 at $1.33 EPS. Its estimates imply that the investment case remains dependent on successful clinical and commercial execution.
• Negative Sentiment: HC Wainwright lowered several future earnings forecasts. The firm reduced its Q3 2026 EPS estimate to negative $0.91 from negative $0.70 and its Q4 2026 estimate to negative $0.94 from negative $0.72. It also cut full-year 2027 EPS to negative $3.65 from negative $2.78, full-year 2028 EPS to negative $2.61 from negative $1.67, and full-year 2029 EPS to $1.33 from $1.86. These revisions suggest higher expected losses and a slower path to profitability.
• Negative Sentiment: Recent quarterly results missed expectations. Vor reported a quarterly loss of $0.80 per share versus the consensus estimate of a $0.69 loss, an unfavorable earnings surprise that pressured the stock. Analysts expect the company to remain unprofitable during the current fiscal year. Vor Biopharma Stock Price Down Following Weak Earnings

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).